Posts Tagged ‘HIVACAT’

Friday February 17th, 2017

A therapeutic HIV vaccine clinical trial induces viral control in 5 people without taking antiretroviral therapy

A therapeutic HIV vaccine clinical trial showed, for the first time, that in some cases the immune system of HIV infected people can be reeducated to control the virus for long periods without taking antiretroviral treatment. In particular, 5 out of 13 participants who stopped treatment (38.5%) have been controlling the virus for 5, 13, 17, 20 and 27 weeks, respectively. The study, still ongoing, is conducted in Barcelona and tests a vaccine developed by researchers at Oxford University in combination with a drug, romidepsin, able to awaken latent viruses in the body. The study is conducted by IrsiCaixa and the Fight AIDS Foundation and performed at the ospital Clínic de Barcelona-IDIBAPS, the Germans Trias i Pujol University Hospital (Barcelona) and the community center BCN Checkpoint. Read the rest of this entry »

Comments Closed
Tuesday January 12th, 2016

Aelix Therapeutics gets €11.5M for therapeutic HIV vaccine

Aelix Therapeutics, a drug development company created from the HIVACAT project and specialized in the discovery and development of immunotherapies against HIV infection, has completed a funding round of €11.5 M. Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a syndicate of new investors including Johnson & Johnson Innovation – JJDC Inc. (“JJDC”), and Caixa Capital Risc, the venture capital division of Spain’s leading financial group, ‘la Caixa’. Doctors Josep M. Gatell, head of the Infectious Diseases Department at Hospital Clínic and IDIBAPS, Bonaventura Clotet and Christian Brander, from the Institute for AIDS Research (IrsiCaixa), and Jordi Naval, are co-founders of the company and in charge of this project.

Read the rest of this entry »

Comments Closed
Wednesday September 25th, 2013

Experts to report on advances in the search for the ultimate HIV prevention tool – a vaccine – at AIDS vaccine 2013

More than 500 research studies outlining the latest advances and obstacles in the search for an AIDS vaccine will be presented and debated at AIDS Vaccine 2013, the world’s only scientific meeting dedicated exclusively to HIV vaccine research. The conference, which runs Monday, 7 October through Thursday, 10 October, will bring more than 1,000 of the world’s leading vaccine researchers, funders and policy makers to the International Convention Center in Barcelona, Spain for four days of exchange, debate and direction-setting for the field.

AIDS Vaccine 2013 is organized by the Global HIV Vaccine Enterprise and by this year’s local conference hosts, the HIVACAT Program for HIV Vaccine Research, based in Barcelona. A vaccine that could help to stop the global HIV/AIDS epidemic is one of the most-sought-after goals of modern scientific research, and among the most complex scientific challenges ever undertaken.

Read the rest of this entry »

Comments Closed
Wednesday January 02nd, 2013

A therapeutic dendritic cell vaccine for HIV-1 infection controls virus replication temporarily

Combination antiretroviral therapy (cART) is a success of modern medicine that greatly improves survival and quality of life of HIV-1–infected patients. The major drawback is that cART must be maintained indefinitely causing inconveniences to patients, potential long term toxicities and carrying elevated economical cost. Research teams across the globe work to find an alternative to “cART for life”, such as inducing HIV-1–specific immune responses to control viral replication after discontinuation of cART. Investigators from the AIDS and Infectious Diseases team of the Hospital Clínic/IDIBAPS at University of Barcelona, led by Dr. Josep Maria Gatell, report today in Science Translational Medicine the safety, tolerability, immunogenicity and virologic response results obtained with a new therapeutic vaccine candidate.


Watch it on Youtube in English.

Read the rest of this entry »

Comments Closed
Thursday December 27th, 2012

Studies from Hospital Clínic and IDIBAPS in the Spanish Science Top5 of the year

2012 is ending, a difficult year also for science due to the crisis affecting much of the world. Despite this, it’s not all are bad news. The spanish researchers continue making relevant contributions to the international scientific scene. The website Materia made a top five of the Spanish scientific initiatives of the past year. In this ranking, there are three studies involving professionals from the Hospital Clínic and the IDIBAPS.

Read the rest of this entry »

Comments Closed
Tuesday September 25th, 2012

HIVACAT has been licensed by the CSIC to develop a vaccine against HIV

hivacat

The HIVACAT program for the development of this vaccine today announced the obtention of a license to advance in the development of a possible vaccine against HIV —the virus that causes AIDS. The license includes a vaccine candidate called “MVA-B”, developed by researcher Mariano Esteban from the Spanish National Research Council (CSIC).

The agreement has been formalized by ESTEVE and the IrsiCaixa Institute for AIDS Research on behalf of HIVACAT. Research, however, will also be conducted at the Hospital Clínic de Barcelona —also part of the HIVACAT consortium.

The obtention of this license coincides with the first anniversary of the presentation in Madrid of very promising results on its efficacy as a preventive vaccine. These results were obtained in a study conducted jointly by the Hospital Clínic of Barcelona and the Gregorio Marañón Hospital of Madrid.

Read the rest of this entry »

Comments Closed
Page 1 of 212